Journal
ACS APPLIED MATERIALS & INTERFACES
Volume 8, Issue 23, Pages 14430-14441Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acsami.6b04286
Keywords
antibodies; apoferritin; doxorubicin; nanomedicine; targeted drug delivery
Funding
- Grant Agency of the Czech Republic (NANOCHEMO) [GA CR 14-18344S]
- Ministry of Health of the Czech Republic [00064203]
- IGA MENDELU [IP_28/2016]
- CEITEC [LQ1601]
Ask authors/readers for more resources
Herein, we describe a novel approach for targeting of ubiquitous protein apoferritin (APO)-encapsulating doxorubicin (DOX) to prostate cancer using antibodies against prostate specific membrane antigen (PSMA). The conjugation of anti-PSMA antibodies and APO was carried out using HWRGWVC heptapeptide, providing their site-directed orientation. The prostate cancer-targeted and nontargeted nanocarriers were tested using LNCaP and HUVEC cell lines. A total of 90% of LNCaP cells died after treatment with DOX (0.25 mu M) or DOX in nontargeted and prostate-cancer-targeted APO, proving that the encapsulated DOX toxicity for LNCaP cells remained the same. Free DOX showed higher toxicity for nonmalignant cells, whereas the toxicity was lower after treatment with the same dosage of APO-encapsulated DOX (APODOX) and even more in prostate-cancer-targeted APODOX. Hemolytic assay revealed exceptional hemocompatibility of the entire nanocarrier. The APO encapsulation mechanism ensures applicability using a wide variety of chemotherapeutic drugs, and the presented surface modification enables targeting to various tumors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available